Effect of recombinant adenoviruses-p53 anticancer injection (Gendicine) combined with human monoclonal antibody to EGFR (h-R3) on esophageal cancer cells with different radiosensitivities

Objective: To observe the effect of recombinant adenoviruses-p53 anticancer injection (Gendicine) combined with a human monoclonal antibody to EGFR (h-R3) on esophageal cancer cells with different radiosensitivities. Methods: The inhibition effect of cell growth and the influence by h-R3 and Gendicine were measured with MTT method. Changes of cell cycle and expressions of Bax and Bcl-2 after treatment with h-R3 and Gendicine were detected by FCM. Results: h-R3, Gendicine and every experimental group all showed the antiproliferative effect in vitro growth profile of each esophageal cell line. Inhibition rate of the simultaneous administration was higher than h-R3 or the Gendicine group. At 12 hours after exposure to h-R3 and Gendicine, FCM analysis demonstrated that h-R3 and Gendicine treatment induced accumulation of TE13 cells in G1, with statistical significance (P<0.05). While there was a slight accumulation of TEI3R120 cells in G1 phase but there was no significance (P>0.05). At 12 hours after treatment with h-R3 and Gendicine, the pro-apoptotic Bax expression was increased and anti apoptotic Bel-2 expression was decreased, with no significant difference (P>0.05). Conclusions: The anti-proliferation effect of h-R3 and Gendicine was observed on different radiosensitivities esophageal cancer cells, which may be concerned with accumulation of cells in G1 phase. But the mechanism needs to be studied further. (authors)